Related Experiment Videos
Ceftriaxone in the treatment of bacterial meningitis in children
Insights
This study on pediatric meningitis found that a single daily dose of ceftriaxone is as effective as twice-daily dosing. This simpler regimen is preferable for treating bacterial meningitis in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Meningitis remains a significant cause of morbidity and mortality in children.
- Ceftriaxone is a commonly used antibiotic for bacterial meningitis.
- Optimizing antibiotic dosing regimens is crucial for effective treatment and patient adherence.
Purpose of the Study:
- To compare the clinical outcomes of ceftriaxone administered once daily versus twice daily in pediatric patients with meningitis.
- To evaluate the therapeutic efficacy and safety of a simplified ceftriaxone dosing schedule.
Main Methods:
- A cohort of 24 pediatric patients with culture-confirmed meningitis was studied.
- Patients received ceftriaxone at varying doses.
- Clinical outcomes were assessed and compared between different dosing frequencies.
Main Results:
- No significant difference in clinical outcomes was observed between once-daily and twice-daily ceftriaxone dosing.
- A favorable therapeutic outcome was achieved in 22 out of 24 patients (91.7%).
- The single daily dose regimen was identified as preferable.
Conclusions:
- Once-daily ceftriaxone is a viable and effective alternative to twice-daily dosing for pediatric meningitis.
- Simplifying the dosing schedule can improve treatment adherence and potentially reduce healthcare costs.
- Further pharmacokinetic and bacteriological analyses support these findings.
Abstract:
A total of 24 pediatric patients with a diagnosis of meningitis, confirmed by positive CFS culture, were enrolled in the study. All patients received ceftriaxone in different doses. No difference in clinical outcome was found between the patients who received ceftriaxone twice a day and the 11 who received the drug as a single daily dose. The latter dosage proves to be preferable. The therapeutic outcome in this series of patients was 22 cured and 2 failures. Bacteriological and pharmacokinetic findings are discussed.